Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome
Abstract Trimethylamine-N-oxide (TMAO), a derivative from the gut microbiota metabolite trimethylamine (TMA), has been identified to be an independent risk factor for promoting atherosclerosis. Evidences suggest that berberine (BBR) could be used to treat obesity, diabetes and atherosclerosis, howev...
Guardado en:
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0f86d6cd8abd41db8c4a1703821317e7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:0f86d6cd8abd41db8c4a1703821317e7 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:0f86d6cd8abd41db8c4a1703821317e72021-12-02T14:26:17ZBerberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome10.1038/s41522-021-00205-82055-5008https://doaj.org/article/0f86d6cd8abd41db8c4a1703821317e72021-04-01T00:00:00Zhttps://doi.org/10.1038/s41522-021-00205-8https://doaj.org/toc/2055-5008Abstract Trimethylamine-N-oxide (TMAO), a derivative from the gut microbiota metabolite trimethylamine (TMA), has been identified to be an independent risk factor for promoting atherosclerosis. Evidences suggest that berberine (BBR) could be used to treat obesity, diabetes and atherosclerosis, however, its mechanism is not clear mainly because of its poor oral bioavailability. Here, we show that BBR attenuated TMA/TMAO production in the C57BL/6J and ApoE KO mice fed with choline-supplemented chow diet, and mitigated atherosclerotic lesion areas in ApoE KO mice. Inhibition of TMA/TMAO production by BBR-modulated gut microbiota was proved by a single-dose administration of d9-choline in vivo. Metagenomic analysis of cecal contents demonstrated that BBR altered gut microbiota composition, microbiome functionality, and cutC/cntA gene abundance. Furthermore, BBR was shown to inhibit choline-to-TMA conversion in TMA-producing bacteria in vitro and in gut microbial consortium from fecal samples of choline-fed mice and human volunteers, and the result was confirmed by transplantation of TMA-producing bacteria in mice. These results offer new insights into the mechanisms responsible for the anti-atherosclerosis effects of BBR, which inhibits commensal microbial TMA production via gut microbiota remodeling.Xingxing LiChunyan SuZhibo JiangYuxin YangYue ZhangMengxia YangXiumin ZhangYu DuJin ZhangLi WangJiandong JiangBin HongNature PortfolioarticleMicrobial ecologyQR100-130ENnpj Biofilms and Microbiomes, Vol 7, Iss 1, Pp 1-14 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Microbial ecology QR100-130 |
spellingShingle |
Microbial ecology QR100-130 Xingxing Li Chunyan Su Zhibo Jiang Yuxin Yang Yue Zhang Mengxia Yang Xiumin Zhang Yu Du Jin Zhang Li Wang Jiandong Jiang Bin Hong Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome |
description |
Abstract Trimethylamine-N-oxide (TMAO), a derivative from the gut microbiota metabolite trimethylamine (TMA), has been identified to be an independent risk factor for promoting atherosclerosis. Evidences suggest that berberine (BBR) could be used to treat obesity, diabetes and atherosclerosis, however, its mechanism is not clear mainly because of its poor oral bioavailability. Here, we show that BBR attenuated TMA/TMAO production in the C57BL/6J and ApoE KO mice fed with choline-supplemented chow diet, and mitigated atherosclerotic lesion areas in ApoE KO mice. Inhibition of TMA/TMAO production by BBR-modulated gut microbiota was proved by a single-dose administration of d9-choline in vivo. Metagenomic analysis of cecal contents demonstrated that BBR altered gut microbiota composition, microbiome functionality, and cutC/cntA gene abundance. Furthermore, BBR was shown to inhibit choline-to-TMA conversion in TMA-producing bacteria in vitro and in gut microbial consortium from fecal samples of choline-fed mice and human volunteers, and the result was confirmed by transplantation of TMA-producing bacteria in mice. These results offer new insights into the mechanisms responsible for the anti-atherosclerosis effects of BBR, which inhibits commensal microbial TMA production via gut microbiota remodeling. |
format |
article |
author |
Xingxing Li Chunyan Su Zhibo Jiang Yuxin Yang Yue Zhang Mengxia Yang Xiumin Zhang Yu Du Jin Zhang Li Wang Jiandong Jiang Bin Hong |
author_facet |
Xingxing Li Chunyan Su Zhibo Jiang Yuxin Yang Yue Zhang Mengxia Yang Xiumin Zhang Yu Du Jin Zhang Li Wang Jiandong Jiang Bin Hong |
author_sort |
Xingxing Li |
title |
Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome |
title_short |
Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome |
title_full |
Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome |
title_fullStr |
Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome |
title_full_unstemmed |
Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome |
title_sort |
berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-n-oxide production via manipulating the gut microbiome |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/0f86d6cd8abd41db8c4a1703821317e7 |
work_keys_str_mv |
AT xingxingli berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT chunyansu berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT zhibojiang berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT yuxinyang berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT yuezhang berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT mengxiayang berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT xiuminzhang berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT yudu berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT jinzhang berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT liwang berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT jiandongjiang berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome AT binhong berberineattenuatescholineinducedatherosclerosisbyinhibitingtrimethylamineandtrimethylaminenoxideproductionviamanipulatingthegutmicrobiome |
_version_ |
1718391353106235392 |